---
title: "CryoPort: Raised Price Target on Strong Q4 Beat, Upbeat 2026 Outlook, and Path to Positive EBITDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277742173.md"
description: "Needham analyst David Saxon has reiterated a Buy rating on CryoPort, raising the price target to $13.00 following a strong Q4 2025 performance and an optimistic 2026 outlook. The company's revenue exceeded expectations, particularly in its Life Sciences Services segment, and it is projected to achieve positive adjusted EBITDA in the second half of 2026. Roth MKM also maintains a Buy rating with a $15.00 price target, reflecting confidence in CryoPort's growth trajectory and improving profitability."
datetime: "2026-03-04T07:35:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277742173.md)
  - [en](https://longbridge.com/en/news/277742173.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277742173.md)
---

# CryoPort: Raised Price Target on Strong Q4 Beat, Upbeat 2026 Outlook, and Path to Positive EBITDA

Needham analyst David Saxon reiterated a Buy rating on CryoPort today and set a price target of $13.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

David Saxon has given his Buy rating due to a combination of factors, primarily CryoPort’s stronger‑than‑expected fourth‑quarter 2025 revenue, which was fueled by robust performance in its Life Sciences Services segment. In addition, management’s 2026 revenue outlook came in above the Street’s expectations at the midpoint, signaling confidence in the company’s growth trajectory.

He also highlights that CryoPort anticipates turning adjusted EBITDA positive in the second half of 2026 as operating expenses become more efficient, indicating improving profitability. In light of this operational momentum and the favorable forward guidance, Saxon not only reiterates his Buy recommendation but also increases his price target to $13, reflecting a more optimistic valuation framework.

In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $15.00 price target.

### Related Stocks

- [CYRX.US](https://longbridge.com/en/quote/CYRX.US.md)

## Related News & Research

- [CryoPort Q4 2025 earnings preview](https://longbridge.com/en/news/277528873.md)
- [CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares](https://longbridge.com/en/news/279355113.md)
- [Hope Bancorp to Report Financial Results for the First Quarter Ended March 31, 2026, on Tuesday, April 28, 2026 | HOPE Stock News](https://longbridge.com/en/news/282682067.md)
- [trivago N.V.'s First Quarter 2026 Earnings Release Scheduled for May 5, 2026; Webcast Scheduled for May 6, 2026 | TRVG Stock News](https://longbridge.com/en/news/282808060.md)
- [CAI Marks Thirty Years Advancing Operational Readiness and Excellence Across Life Sciences and Mission-Critical Industries](https://longbridge.com/en/news/282541838.md)